13. April 2023 – On 6 April 2023, ImmunoGen, Inc. (Nasdaq: IMGN), a leader in antibody-drug conjugates (ADCs) for the treatment of cancer, announced the closed of a term loan financing for up to USD 125 million with funds managed by Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds.

Walder Wyss team, led by Tervel Stoyanov (Counsel, Banking & Finance), advised the funds managed by Pharmakon Advisors, LP.